Multidrug resistance associated proteins in multindrung resistance

Chinese Journal of Cancer

Volumn 31, Issue 2, 2012, Pages 58-72

  Sodani, Kamlesh ^a   Patel, Atish ^a   Kathawala, Rishil J ^a   Chen, Zhe Sheng ^a  

^a ST JOHN'S UNIVERSITY   (United States)

Author keywords

ABC transporter; Chemotherapy; Multidrug resistance (MDR); Multidrug resistance protein (MRP)

Indexed keywords

CARRIER PROTEINS AND BINDING PROTEINS; MULTIDRUG RESISTANCE PROTEIN; MULTIDRUG RESISTANCE PROTEIN 1; MULTIDRUG RESISTANCE PROTEIN 2; MULTIDRUG RESISTANCE PROTEIN 3; MULTIDRUG RESISTANCE PROTEIN 4; MULTIDRUG RESISTANCE PROTEIN 5; MULTIDRUG RESISTANCE PROTEIN 6; MULTIDRUG RESISTANCE PROTEIN 7; MULTIDRUG RESISTANCE PROTEIN 8; MULTIDRUG RESISTANCE PROTEIN 89; UNCLASSIFIED DRUG;

AMINO ACID ANALYSIS; CANCER RESISTANCE; HUMAN; MULTIDRUG RESISTANCE; NONHUMAN; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN LOCALIZATION; PROTEIN STRUCTURE; PROTEIN TRANSPORT; REVIEW; SEQUENCE ANALYSIS; STRUCTURE ANALYSIS;

ANTINEOPLASTIC AGENTS; BIOLOGICAL TRANSPORT; DRUG RESISTANCE, MULTIPLE; DRUG RESISTANCE, NEOPLASM; GLUTATHIONE; HUMANS; LEUKOTRIENE C4; MULTIDRUG RESISTANCE-ASSOCIATED PROTEINS; NEOPLASMS; TISSUE DISTRIBUTION;

EID: 84863295466     PISSN: 1000467X     EISSN: 1944446X     Source Type: Journal    
DOI: 10.5732/cjc.011.10329     Document Type: Review

References (188)

1. Gottesman MM, Fojo T, Bates SE. Multidrug resistance in cancer: role of ATP-dependent transporters. Nat Rev Cancer, 2002, 2:48-58.
2. Jemal A, Center MM, Ward E, et al. Cancer occurrence. Methods Mol Biol, 2009, 471:3-29.
3. Gottesman MM. Mechanisms of cancer drug resistance. Annu Rev Med, 2002, 53:615-627.
4. Loe DW, Deeley RG, Cole SP. Characterization of vincristine transport by the M (r) 190 000 multidrug resistance protein (MRP): evidence for cotransport with reduced glutathione. Cancer Res, 1998, 58:5130-5136.
5. Redmond KM, Wilson TR, Johnston PG, et al. Resistance mechanisms to cancer chemotherapy. Front Biosci, 2008, 13: 5138-5154.
6. Dean M, Rzhetsky A, Allikmets R. The human ATP-binding cassette (ABC) transporter superfamily. Genome Res, 2001, 11: 1156-1166.
7. Dean M, Annilo T. Evolution of the ATP-binding cassette (ABC) transporter superfamily in vertebrates. Annu Rev Genomics Hum Genet, 2005, 6:123-142.
8. Dean M, Allikmets R. Complete characterization of the human ABC gene family. J Bioenerg Biomembr, 2001, 33:475-479.
9. Keppler D. Multidrug resistance proteins (MRPs, ABCCs): importance for pathophysiology and drug therapy. Handb Exp Pharmacol, 2011, 201:299-323.
10. Cole SP, Bhardwaj G, Gerlach JH, et al. Overexpression of a transporter gene in a multidrug-re sistant human lung cancer cell line. Science, 1992, 258:1650-1654.
11. Deeley RG, Westlake C, Cole SP. Transmembrane transport of endo-and xenobiotics by mammalian ATP-binding cassette multidrug resistance proteins. Physiol Rev, 2006, 86:849-899.
12. Hollenstein K, Dawson RJ, Locher KP. Structure and mechanism of ABC transporter proteins. Curr Opin Struct Biol, 2007, 17:412-418.
13. Marquardt D, McCrone S, Center MS. Mechanisms of multidrug resistance in HL60 cells: detection of resistance-associated proteins with antibodies against synthetic peptides that correspond to the deduced sequence of P-glycoprotein. Cancer Res, 1990, 50:1426-1430.
14. Marsh W, Sicheri D, Center MS. Isolation and characterization of adriamycin-resistant HL-60 cells which are not defective in the initial intracellular accumulation of drug. Cancer Res, 1986, 46:4053-4057.
15. Marsh W, Center MS. Adriamycin resistance in HL60 cells and accompanying modification of a surface membrane protein contained in drug-sensitive cells. Cancer Res, 1987, 47:5080-5086.
16. McGrath T, Latoud C, Arnold ST, et al. Mechanisms of multidrug resistance in HL60 cells. Analysis of resistance associated membrane proteins and levels of MDR gene expression. Biochem Pharmacol, 1989, 38:3611-3619.
17. Bakos E, Evers R, Szakacs G, et al. Functional multidrug resistance protein (MRP1) lacking the N-te rminal transmembrane domain. J Biol Chem, 1998, 273:32167-32175.
18. Kruh GD, Belinsky MG. The MRP family of drug efflux pumps. Oncogene, 2003, 22:7537-7552.
19. Flens MJ, Zaman GJ, van der Valk P, et al. Tissue distribution of the multidrug resistance protein. Am J Pathol, 1996, 148: 1237-1247.
20. Wright SR, Boag AH, Valdimarsson G, et al. Immunohistochemical detection of multidrug resistance protein in human lung cancer and normal lung. Clin Cancer Res, 1998, 4:2279-2289.
21. Brechot JM, Hurbain I, Fajac A, et al. Different pattern of MRP localization in ciliated and basal cells from human bronchial epithelium. J Histochem Cytochem, 1998, 46:513-517.
22. St-Pierre MV, Serrano MA, Macias RI, et al. Expression of members of the multidrug resistance protein family in human term placenta. Am J Physiol Regul Integr Comp Physiol, 2000, 279:R1495-R1503.
23. Bakos E, Hegedus T, Hollo Z, et al. Membrane topology and glycosylation of the human multidrug resistance-associated protein. J Biol Chem, 1996, 271:12322-12326.
24. Hipfner DR, Almquist KC, Leslie EM, et al. Membrane topology of the multidrug resistance protein (MRP). A study of glycosylation-site mutants reveals an extracytosolic NH2 terminus. J Biol Chem, 1997, 272:23623-23630.
25. Cole SP, Sparks KE, Fraser K, et al. Pharmacological characterization of multidrug resistant MRP-transfected human tumor cells. Cancer Res, 1994, 54:5902-5910.
26. Zaman GJ, Flens MJ, van Leusden MR, et al. The human multidrug resistance-associated protein MRP is a plasma membrane drug-efflux pump. Proc Natl Acad Sci U S A, 1994, 91:8822-8826.
27. Breuninger LM, Paul S, Gaughan K, et al. Expression of multidrug resistance-associated protein in NIH/3T3 cells confers multidrug resistance associated with increased drug efflux and altered intracellular drug distribution. Cancer Res, 1995, 55: 5342-5347.
28. Williams GC, Liu A, Knipp G, et al. Direct evidence that saquinavir is transported by multidrug resistance-as sociated protein (MRP1) and canalicular multispecific organic anion transporter (MRP2). Antimicrob Agents Chemother, 2002, 46: 3456-3462.
29. Chen ZS, Furukawa T, Sumizawa T, et al. ATP-de pendent efflux of CPT-11 and SN-38 by the multidrug resistance protein (MRP) and its inhibition by PAK-10 4P. Mol Pharmacol, 1999, 55:921-928.
30. Morrow CS, Peklak-Scott C, Bishwokarma B, et al. Multidrug resistance protein 1 (MRP1, ABCC1) mediates resistance to mitoxantrone via glutathione-de pendent drug efflux. Mol Pharmacol, 2006, 69:1499-1505.
31. Allen JD, Brinkhuis RF, van Deemter L, et al. Extensive contribution of the multidrug transporters P-glycoprotein and Mrp1 to basal drug resistance. Cancer Res, 2000, 60:5761-5766.
32. Lin ZP, Johnson DR, Finch RA, et al. Comparative study of the importance of multidrug resistance-as sociated protein 1 and P-glycoprotein to drug sensitivity in immortalized mouse embryonic fibroblasts. Mol Cancer Ther, 2002, 1:1105-1114.
33. Czyzewski K, Styczynski J. Imatinib is a substrate for various multidrug resistance proteins. Neoplasma, 2009, 56:202-207.
34. Jedlitschky G, Leier I, Buchholz U, et al. ATP-de pendent transport of glutathione S-co njugates by the multidrug resistance-associated protein. Cancer Res, 1994, 54:4833-4836.
35. Leier I, Jedlitschky G, Buchholz U, et al. The MRP gene encodes an ATP-de pendent export pump for leukotriene C4 and structurally related conjugates. J Biol Chem, 1994, 269: 27807-27810.
36. Jedlitschky G, Leier I, Buchholz U, et al. Transport of glutathione, glucuronate, and sulfate conjugates by the MRP gene- encoded conjugate export pump. Cancer Res, 1996, 56: 988-994.
37. Loe DW, Almquist KC, Cole SP, et al. ATP-de pendent 17 beta- estradiol 17-(b eta-D -gl ucuronide) transport by multidrug resistance protein (MRP). Inhibition by cholestatic steroids. J Biol Chem, 1996, 271:9683-9689.
38. Wijnholds J, Evers R, van Leusden MR, et al. Increased sensitivity to anticancer drugs and decreased inflammatory response in mice lacking the multidrug resistance-associated protein. Nat Med, 1997, 3:1275-1279.
39. Evers R, Zaman GJ, van Deemter L, et al. Basolateral localization and export activity of the human multidrug resistance -associated protein in polarized pig kidney cells. J Clin Invest, 1996, 97:1211-1218.
40. Ishikawa T. The ATP-de pendent glutathione S-co njugate export pump. Trends Biochem Sci, 1992, 17:463-468.
41. Kruh GD, Gaughan KT, Godwin A, et al. Expression pattern of MRP in human tissues and adult solid tumor cell lines. J Natl Cancer Inst, 1995, 87:1256-1258.
42. Zaman GJ, Lankelma J, van Tellingen O, et al. Role of glutathione in the export of compounds from cells by the multidrug resistance-associated protein. Proc Natl Acad Sci U S A, 1995, 92:7690-7694.
43. Versantvoort CH, Broxterman HJ, Bagrij T, et al. Regulation by glutathione of drug transport in multidrug resistant human lung tumour cell lines overexpressing multidrug resistance-associated protein. Br J Cancer, 1995, 72:82-89.
44. Renes J, de Vries EG, Nienhuis EF, et al. ATP- and glutathione-de pendent transport of chemotherapeutic drugs by the multidrug resistance protein MRP1. Br J Pharmacol, 1999, 126:681-688.
45. Rappa G, Lorico A, Flavell RA, et al. Evidence that the multidrug resistance protein (MRP) functions as a co-transporter of glutathione and natural product toxins. Cancer Res, 1997, 57:5232-5237.
46. Loe DW, Almquist KC, Deeley RG, et al. Multidrug resistance protein (MRP)-mediated transport of leukotriene C4 and chemotherapeutic agents in membrane vesicles. Demonstration of glutathione-de pendent vincristine transport. J Biol Chem, 1996, 271:9675-9682.
47. Filipits M, Suchomel RW, Dekan G, et al. MRP and MDR1 gene expression in primary breast carcinomas. Clin Cancer Res, 1996, 2:1231-1237.
48. Nooter K, de la Riviere GB, Klijn J, et al. Multidrug resistance protein in recurrent breast cancer. Lancet, 1997, 349:1885-1886.
49. Tiwari AK, Sodani K, Dai CL, et al. Revisiting the ABCs of multidrug resistance in cancer chemotherapy. Curr Pharm Biotechnol, 2011, 12:570-594.
50. Nagengast WB, Oude Munnink TH, Dijkers EC, et al. Multidrug resistance in oncology and beyond: from imaging of drug efflux pumps to cellular drug targets. Methods Mol Biol, 2010, 596:15-31.
51. Buchler M, Konig J, Brom M, et al. CDNA cloning of the hepatocyte canalicular isoform of the multidrug resistance protein, cMrp, reveals a novel conjugate export pump deficient in hyperbilirubinemic mutant rats. J Biol Chem, 1996, 271: 15091-15098.
52. Paulusma CC, Kool M, Bosma PJ, et al. A mutation in the human canalicular multispecific organic anion transporter gene causes the dubin-jo hnson syndrome. Hepatology, 1997, 25: 1539-1542.
53. Mottino AD, Hoffman T, Jennes L, et al. Expression of multidrug resistance-associated protein 2 in small intestine from pregnant and postpartum rats. Am J Physiol Gastrointest Liver Physiol, 2001, 280:G1261-G1273.
54. Schaub TP, Kartenbeck J, Konig J, et al. Expression of the conjugate export pump encoded by the MRP2 gene in the apical membrane of kidney proximal tubules. J Am Soc Nephrol, 1997, 8:1213-1221.
55. Kool M, de Haas M, Scheffer GL, et al. Analysis of expression of cMOAT (MRP2), MRP3, MRP4, and MRP5, homologues of the multidrug resistance -associated protein gene (MRP1), in human cancer cell lines. Cancer Res, 1997, 57:3537-3547.
56. Rost D, Konig J, Weiss G, et al. Expression and localization of the multidrug resistance proteins MRP2 and MRP3 in human gallbladder epithelia. Gastroenterology, 2001, 121:1203-1208.
57. Koike K, Kawabe T, Tanaka T, et al. A canalicular multispecific organic anion transporter (cMOAT) antisense cdna enhances drug sensitivity in human hepatic cancer cells. Cancer Res, 1997, 57:5475-5479.
58. Evers R, Kool M, van Deemter L, et al. Drug export activity of the human canalicular multispecific organic anion transporter in polarized kidney mdck cells expressing cMOAT (MRP2) cDNA. J Clin Invest, 1998, 101:1310-1319.
59. Hooijberg JH, Broxterman HJ, Kool M, et al. Antifolate resistance mediated by the multidrug resistance proteins MRP1 and MRP2. Cancer Res, 1999, 59:2532-2535.
60. Cui Y, Konig J, Buchholz JK, et al. Drug resistance and ATP-dependent conjugate transport mediated by the apical multidrug resistance protein, MRP2, permanently expressed in human and canine cells. Mol Pharmacol, 1999, 55:929-937.
61. Ishikawa T, Ali-Osman F. Glutathione-as sociated cis-diamminedichloroplatinum (II) metabolism and ATP-de pendent efflux from leukemia cells. Molecular characterization of glutathione-pl atinum complex and its biological significance. J Biol Chem, 1993, 268:20116-20125.
62. Evers R, de Haas M, Sparidans R, et al. Vinblastine and sulfinpyrazone export by the multidrug resistance protein MRP2 is associated with glutathione export. Br J Cancer, 2000, 83: 375-383.
63. Nies AT, Keppler D. The apical conjugate efflux pump ABCC2 (MRP2). Pflugers Arch, 2007, 453:643-659.
64. Konig J, Nies AT, Cui Y, et al. Conjugate export pumps of the multidrug resistance protein (MRP) family: localization, substrate specificity, and MRP2-m ediated drug resistance. Biochim Biophys Acta, 1999, 1461:377-394.
65. Kawabe T, Chen ZS, Wada M, et al. Enhanced transport of anticancer agents and leukotriene C4 by the human canalicular multispecific organic anion transporter (cMOAT/MRP2). FEBS Lett, 1999, 456:327-331.
66. Kartenbeck J, Leuschner U, Mayer R, et al. Absence of the canalicular isoform of the MRP gene-encoded conjugate export pump from the hepatocytes in dubin-jo hnson syndrome. Hepatology, 1996, 23:1061-1066.
67. Jansen PL, Peters WH, Lamers WH. Hereditary chronic conjugated hyperbilirubinemia in mutant rats caused by defective hepatic anion transport. Hepatology, 1985, 5:573-579.
68. Hosokawa S, Tagaya O, Mikami T, et al. A new rat mutant with chronic conjugated hyperbilirubinemia and renal glomerular lesions. Lab Anim Sci, 1992, 42:27-34.
69. Hirohashi T, Suzuki H, Ito K, et al. Hepatic expression of multidrug resistance-associated protein-lik e proteins maintained in eisai hyperbilirubinemic rats. Mol Pharmacol, 1998, 53:1068-1075.
70. Narasaki F, Oka M, Nakano R, et al. Human canalicular multispecific organic anion transporter (cMOAT) is expressed in human lung, gastric, and colorectal cancer cells. Biochem Biophys Res Commun, 1997, 240:606-611.
71. Taniguchi K, Wada M, Kohno K, et al. A human canalicular multispecific organic anion transporter (cMOAT) gene is overexpressed in cisplatin-resistant human cancer cell lines with decreased drug accumulation. Cancer Res, 1996, 56: 4124-4129.
72. Korita PV, Wakai T, Shirai Y, et al. Multidrug resistanceassociated protein 2 determines the efficacy of cisplatin in patients with hepatocellular carcinoma. Oncol Rep, 2010, 23: 965-972.
73. Konig J, Rost D, Cui Y, et al. Characterization of the human multidrug resistance protein isoform MRP3 localized to the basolateral hepatocyte membrane. Hepatology, 1999, 29:1156-1163.
74. Kool M, van der Linden M, de Haas M, et al. MRP3, an organic anion transporter able to transport anti-ca ncer drugs. Proc Natl Acad Sci U S A, 1999, 96:6914-6919.
75. Ortiz DF, Li S, Iyer R, et al. MRP3, a new ATP-binding cassette protein localized to the canalicular domain of the hepatocyte. Am J Physiol, 1999, 276:G1493-G1500.
76. Borst P, Zelcer N, van de Wetering K. MRP2 and 3 in health and disease. Cancer Lett, 2006, 234:51-61.
77. Scheffer GL, Kool M, de Haas M, et al. Tissue distribution and induction of human multidrug resistant protein 3. Lab Invest, 2002, 82:193-201.
78. Zeng H, Bain LJ, Belinsky MG, et al. Expression of multidrug resistance protein-3 (multispecific organic anion transporter-D) in human embryonic kidney 293 cells confers resistance to anticancer agents. Cancer Res, 1999, 59:5964-5967.
79. Zelcer N, Saeki T, Reid G, et al. Characterization of drug transport by the human multidrug resistance protein 3 (ABCC3). J Biol Chem, 2001, 276:46400-46407.
80. Lagas JS, Fan L, Wagenaar E, et al. P-glycoprotein (P-gp / Abcb1), Abcc2, and Abcc3 determine the pharmacokinetics of etoposide. Clin Cancer Res, 2010, 16:130-140.
81. Kubo K, Sekine S, Saito M. Compensatory expression of MRP3 in the livers of MRP2-de ficient EHBRs is promoted by DHA intake. Biosci Biotechnol Biochem, 2009, 73:2432-2438.
82. Belinsky MG, Dawson PA, Shchaveleva I, et al. Analysis of the in vivo functions of MRP3. Mol Pharmacol, 2005, 68:160-168.
83. Zeng H, Liu G, Rea PA, et al. Transport of amphipathic anions by human multidrug resistance protein 3. Cancer Res, 2000, 60: 4779-4784.
84. Hirohashi T, Suzuki H, Sugiyama Y. Characterization of the transport properties of cloned rat multidrug resistance associated protein 3 (Mrp3). J Biol Chem, 1999, 274:15181-15185.
85. Nies AT, Konig J, Pfannschmidt M, et al. Expression of the multidrug resistance proteins MRP2 and MRP3 in human hepatocellular carcinoma. Int J Cancer, 2001, 94:492-499.
86. Ohishi Y, Oda Y, Uchiumi T, et al. ATP-binding cassette superfamily transporter gene expression in human primary ovarian carcinoma. Clin Cancer Res, 2002, 8:3767-3775.
87. Plasschaert SL, de Bont ES, Boezen M, et al. Expression of multidrug resistance -associated proteins predicts prognosis in childhood and adult acute lymphoblastic leukemia. Clin Cancer Res, 2005, 11:8661-8668.
88. Russel FG, Koenderink JB, Masereeuw R. Multidrug resistance protein 4 (MRP4/ABCC4): a versatile efflux transporter for drugs and signalling molecules. Trends Pharmacol Sci, 2008, 29:200-207.
89. Schuetz JD, Connelly MC, Sun D, et al. MRP4: a previously unidentified factor in resistance to nucleoside-based antiviral drugs. Nat Med, 1999, 5:1048-1051.
90. Allikmets R, Gerrard B, Hutchinson A, et al. Characterization of the human ABC superfamily: isolation and mapping of 21 new genes using the expressed sequence tags database. Hum Mol Genet, 1996, 5:1649-1655.
91. Lee K, Belinsky MG, Bell DW, et al. Isolation of MOAT-b, a widely expressed multidrug resistance-associated protein/canalicular multispecific organic anion transporter-related transporter. Cancer Res, 1998, 58:2741-2747.
92. Borst P, Evers R, Kool M, et al. A family of drug transporters: the multidrug resistance -associated proteins. J Natl Cancer Inst, 2000, 92:1295-1302.
93. Borst P, de Wolf C, van de Wetering K. Multidrug resistanceassociated proteins 3, 4, and 5. Pflugers Arch, 2007, 453:661-673.
94. Sauna ZE, Nandigama K, Ambudkar SV. Multidrug resistance protein 4 (ABCC4)-mediated ATP hydrolysis: effect of transport substrates and characterization of the post-hydrolysis transition state. J Biol Chem, 2004, 279:48855-48864.
95. Li C, Krishnamurthy PC, Penmatsa H, et al. Spatiotemporal coupling of cAMP transporter to CFTR chloride channel function in the gut epithelia. Cell, 2007, 131:940-951.
96. Zelcer N, Reid G, Wielinga P, et al. Steroid and bile acid conjugates are substrates of human multidrug-resistance protein (MRP) 4 (ATP-binding cassette C4). Biochem J, 2003, 371: 361-367.
97. Hopper-Borge E, Chen ZS, Shchaveleva I, et al. Analysis of the drug resistance profile of multidrug resistance protein 7 (ABCC10): resistance to docetaxel. Cancer Res, 2004, 64: 4927-4930.
98. Rius M, Nies AT, Hummel-Ei senbeiss J, et al. Cotransport of reduced glutathione with bile salts by MRP4 (ABCC4) localized to the basolateral hepatocyte membrane. Hepatology, 2003, 38: 374-384.
99. Adachi M, Sampath J, Lan LB, et al. Expression of MRP4 confers resistance to ganciclovir and compromises bystander cell killing. J Biol Chem, 2002, 277:38998-39004.
100. Chen ZS, Lee K, Walther S, et al. Analysis of methotrexate and folate transport by multidrug resistance protein 4 (ABCC4): MRP4 is a component of the methotrexate efflux system. Cancer Res, 2002, 62:3144-3150.
101. Chen ZS, Lee K, Kruh GD. Transport of cyclic nucleotides and estradiol 17-be ta-D -glucuronide by multidrug resistance protein 4. Resistance to 6-mercaptopurine and 6-th ioguanine. J Biol Chem, 2001, 276:33747-33754.
102. Lai L, Tan TM. Role of glutathione in the multidrug resistance protein 4 (MRP4/ABCC4) -mediated efflux of cAMP and resistance to purine analogues. Biochem J, 2002, 361:497-503.
103. Reid G, Wielinga P, Zelcer N, et al. Characterization of the transport of nucleoside analog drugs by the human multidrug resistance proteins MRP4 and MRP5. Mol Pharmacol, 2003, 63: 1094-1103.
104. Wielinga PR, Reid G, Challa EE, et al. Thiopurine metabolism and identification of the thiopurine metabolites transported by MRP4 and MRP5 overexpressed in human embryonic kidney cells. Mol Pharmacol, 2002, 62:1321-1331.
105. Wu CP, Calcagno AM, Hladky SB, et al. Modulatory effects of plant phenols on human multidrug-re sistance proteins 1, 4 and 5 (ABCC1, 4 and 5). FEBS J, 2005, 272:4725-4740.
106. Wielinga PR, van der Heijden I, Reid G, et al. Characterization of the MRP4- and MRP5-m ediated transport of cyclic nucleotides from intact cells. J Biol Chem, 2003, 278:17664-17671.
107. Hofer AM, Lefkimmiatis K. Extracellular calcium and cAMP: second messengers as third messengers? Physiology (Bethesda), 2007, 22:320-327.
108. Chen C, Slitt AL, Dieter MZ, et al. Up-re gulation of Mrp4 expression in kidney of MRP2-de ficient TR-rats. Biochem Pharmacol, 2005, 70:1088-1095.
109. Denk GU, Soroka CJ, Takeyama Y, et al. Multidrug resistance- associated protein 4 is up-re gulated in liver but down-regulated in kidney in obstructive cholestasis in the rat. J Hepatol, 2004, 40:585-591.
110. Klokouzas A, Wu CP, van Veen HW, et al. CGMP and glutathione-co njugate transport in human erythrocytes. Eur J Biochem, 2003, 270:3696-3708.
111. Sager G, Orbo A, Pettersen RH, et al. Export of guanosine 3', 5'-cyclic monophosphate (cGMP) from human erythrocytes characterized by inside-out membrane vesicles. Scand J Clin Lab Invest, 1996, 56:289-293.
112. Schultz C, Vaskinn S, Kildalsen H, et al. Cyclic AMP stimulates the cyclic GMP egression pump in human erythrocytes: effects of probenecid, verapamil, progesterone, theophylline, ibmx, forskolin, and cyclic AMP on cyclic GMP uptake and association to inside-out vesicles. Biochemistry, 1998, 37:1161-1166.
113. Sundkvist E, Jaeger R, Sager G. Pharmacological characterization of the ATP-de pendent low K(m) guanosine 3', 5'-cyclic monophosphate (cGMP) transporter in human erythrocytes. Biochem Pharmacol, 2002, 63:945-949.
114. Wu CP, Woodcock H, Hladky SB, et al. CGMP (guanosine 3', 5'-cy clic monophosphate) transport across human erythrocyte membranes. Biochem Pharmacol, 2005, 69:1257-1262.
115. Lin ZP, Zhu YL, Johnson DR, et al. Disruption of cAMP and prostaglandin E2 transport by multidrug resistance protein 4 deficiency alters cAMP-mediated signaling and nociceptive response. Mol Pharmacol, 2008, 73:243-251.
116. Rius M, Hummel-Ei senbeiss J, Hofmann AF, et al. Substrate specificity of human ABCC4 (MRP4)-mediated cotransport of bile acids and reduced glutathione. Am J Physiol Gastrointest Liver Physiol, 2006, 290:G640-G649.
117. Van Aubel RA, Smeets PH, van den Heuvel JJ, et al. Human organic anion transporter MRP4 (ABCC4) is an efflux pump for the purine end metabolite urate with multiple allosteric substrate binding sites. Am J Physiol Renal Physiol, 2005, 288:F327-F333.
118. Schuetz EG, Strom S, Yasuda K, et al. Disrupted bile acid homeostasis reveals an unexpected interaction among nuclear hormone receptors, transporters, and cytochrome P450. J Biol Chem, 2001, 276:39411-39418.
119. Aleksunes LM, Slitt AM, Cherrington NJ, et al. Differential expression of mouse hepatic transporter genes in response to acetaminophen and carbon tetrachloride. Toxicol Sci, 2005, 83: 44-52.
120. Aleksunes LM, Scheffer GL, Jakowski AB, et al. Coordinated expression of multidrug resistance-associated proteins (MRPs) in mouse liver during toxicant-induced injury. Toxicol Sci, 2006, 89:370-379.
121. Adachi M, Reid G, Schuetz JD. Therapeutic and biological importance of getting nucleotides out of cells: a case for the ABC transporters, MRP4 and 5. Adv Drug Deliv Rev, 2002, 54: 1333-1342.
122. Hitzl M, Klein K, Zanger UM, et al. Influence of omeprazole on multidrug resistance protein 3 expression in human liver. J Pharmacol Exp Ther, 2003, 304:524-530.
123. Haimeur A, Conseil G, Deeley RG, et al. The MRP-related and BCRP/ABCG2 multidrug resistance proteins: biology, substrate specificity and regulation. Curr Drug Metab, 2004, 5:21-53.
124. Belinsky MG, Bain LJ, Balsara BB, et al. Characterization of MOAT-C and MOAT-D, new members of the MRP/cMOAT subfamily of transporter proteins. J Natl Cancer Inst, 1998, 90: 1735-1741.
125. McAleer MA, Breen MA, White NL, et al. Pabc11 (also known as MOAT-C and MRP5), a member of the ABC family of proteins, has anion transporter activity but does not confer multidrug resistance when overexpressed in human embryonic kidney 293 cells. J Biol Chem, 1999, 274:23541-23548.
126. Wijnholds J, Mol CA, van Deemter L, et al. Multidrug-resistance protein 5 is a multispecific organic anion transporter able to transport nucleotide analogs. Proc Natl Acad Sci U S A, 2000, 97:7476-7481.
127. Carvajal JA, Germain AM, Huidobro-Toro JP, et al. Molecular mechanism of cGMP-mediated smooth muscle relaxation. J Cell Physiol, 2000, 184:409-420.
128. Moncada S, Palmer RM, Higgs EA. Nitric oxide: physiology, pathophysiology, and pharmacology. Pharmacol Rev, 1991, 43: 109-142.
129. Dazert P, Meissner K, Vogelgesang S, et al. Expression and localization of the multidrug resistance protein 5 (MRP5/ ABCC5), a cellular export pump for cyclic nucleotides, in human heart. Am J Pathol, 2003, 163:1567-1577.
130. Flesch M, Kilter H, Cremers B, et al. Acute effects of nitric oxide and cyclic GMP on human myocardial contractility. J Pharmacol Exp Ther, 1997, 281:1340-1349.
131. Touyz RM, Picard S, Schiffrin EL, et al. Cyclic GMP inhibits a pharmacologically distinct Na + /H + exchanger variant in cultured rat astrocytes via an extracellular site of action. J Neurochem, 1997, 68:1451-1461.
132. Vogelgesang S, Kunert-Keil C, Cascorbi I, et al. Expression of multidrug transporters in dysembryoplastic neuroepithelial tumors causing intractable epilepsy. Clin Neuropathol, 2004, 23: 223-231.
133. Nies AT, Jedlitschky G, Konig J, et al. Expression and immunolocalization of the multidrug resistance proteins, MRP1- MRP6 (ABCC1-ABCC6), in human brain. Neuroscience, 2004, 129:349-360.
134. Nies AT, Konig J, Cui Y, et al. Structural requirements for the apical sorting of human multidrug resistance protein 2 (ABCC2). Eur J Biochem, 2002, 269:1866-1876.
135. Nies AT, Spring H, Thon WF, et al. Immunolocalization of multidrug resistance protein 5 in the human genitourinary system. J Urol, 2002, 167:2271-2275.
136. Robbins BL, Connelly MC, Marshall DR, et al. A human T lymphoid cell variant resistant to the acyclic nucleoside phosphonate 9-(2 -phosphonylmethoxyethyl) adenine shows a unique combination of a phosphorylation defect and increased efflux of the agent. Mol Pharmacol, 1995, 47:391-397.
137. Pratt S, Shepard RL, Kandasamy RA, et al. The multidrug resistance protein 5 (ABCC5) confers resistance to 5-fluorouracil and transports its monophosphorylated metabolites. Mol Cancer Ther, 2005, 4:855-863.
138. Jedlitschky G, Burchell B, Keppler D. The multidrug resistance protein 5 functions as an ATP-de pendent export pump for cyclic nucleotides. J Biol Chem, 2000, 275:30069-30074.
139. Sundkvist E, Jaeger R, Sager G. Leukotriene C(4) (LTC (4)) does not share a cellular efflux mechanism with cGMP: characterisation of cGMP transport by uptake to inside-out vesicles from human erythrocytes. Biochim Biophys Acta, 2000, 1463:121-130.
140. Garthwaite J. Neural nitric oxide signalling. Trends Neurosci, 1995, 18:51-52.
141. Kool M, van der Linden M, de Haas M, et al. Expression of human MRP6, a homologue of the multidrug resistance protein gene MRP1, in tissues and cancer cells. Cancer Res, 1999, 59: 175-182.
142. Cai J, Daoud R, Alqawi O, et al. Nucleotide binding and nucleotide hydrolysis properties of the ABC transporter MRP6 (ABCC6). Biochemistry, 2002, 41:8058-8067.
143. Belinsky MG, Kruh GD. MOAT-E (ARA) is a full-le ngth MRP/ cMOAT subfamily transporter expressed in kidney and liver. Br J Cancer, 1999, 80:1342-1349.
144. Madon J, Hagenbuch B, Landmann L, et al. Transport function and hepatocellular localization of Mrp6 in rat liver. Mol Pharmacol, 2000, 57:634-641.
145. Beck K, Hayashi K, Nishiguchi B, et al. The distribution of ABCC6 in normal mouse tissues suggests multiple functions for this ABC transporter. J Histochem Cytochem, 2003, 51:887-902.
146. Bergen AA, Plomp AS, Schuurman EJ, et al. Mutations in ABCC6 cause pseudoxanthoma elasticum. Nat Genet, 2000, 25: 228-231.
147. Ringpfeil F, Lebwohl MG, Christiano AM, et al. Pseudoxanthoma elasticum: mutations in the MRP6 gene encoding a transmembrane ATP-binding cassette (ABC) transporter. Proc Natl Acad Sci U S A, 2000, 97:6001-6006.
148. Struk B, Cai L, Zach S, et al. Mutations of the gene encoding the transmembrane transporter protein ABC-C 6 cause pseudoxanthoma elasticum. J Mol Med (Berl), 2000, 78:282-286.
149. Gheduzzi D, Guidetti R, Anzivino C, et al. ABCC6 mutations in italian families affected by pseudoxanthoma elasticum (PXE). Hum Mutat, 2004, 24:438-439.
150. Cai L, Lumsden A, Guenther UP, et al. A novel Q378X mutation exists in the transmembrane transporter protein ABCC6 and its pseudogene: implications for mutation analysis in pseudoxanthoma elasticum. J Mol Med (Berl), 2001, 79:536-546.
151. Meloni I, Rubegni P, De Aloe G, et al. Pseudoxanthoma elasticum: Point mutations in the ABCC6 gene and a large deletion including also ABCC1 and MYH11. Hum Mutat, 2001, 18:85.
152. Ringpfeil F, Nakano A, Uitto J, et al. Compound heterozygosity for a recurrent 16.5-kb Alu-m ediated deletion mutation and single-ba se-pa ir substitutions in the ABCC6 gene results in pseudoxanthoma elasticum. Am J Hum Genet, 2001, 68:642-652.
153. Hu X, Plomp A, Wijnholds J, et al. ABCC6/MRP6 mutations: further insight into the molecular pathology of pseudoxanthoma elasticum. Eur J Hum Genet, 2003, 11:215-224.
154. Maher JM, Slitt AL, Cherrington NJ, et al. Tissue distribution and hepatic and renal ontogeny of the multidrug resistance -associated protein (MRP) family in mice. Drug Metab Dispos, 2005, 33:947-955.
155. Maher JM, Cherrington NJ, Slitt AL, et al. Tissue distribution and induction of the rat multidrug resistance-associated proteins 5 and 6. Life Sci, 2006, 78:2219-2225.
156. Scheffer GL, Hu X, Pijnenborg AC, et al. MRP6 (ABCC6) detection in normal human tissues and tumors. Lab Invest, 2002, 82:515-518.
157. Sinko E, Ilias A, Ujhelly O, et al. Subcellular localization and N- glycosylation of human ABCC6, expressed in MDCKII cells. Biochem Biophys Res Commun, 2003, 308:263-269.
158. Uitto J, Pulkkinen L, Ringpfeil F. Molecular genetics of pseudoxanthoma elasticum: a metabolic disorder at the environment-ge nome interface? Trends Mol Med, 2001, 7:13-17.
159. Belinsky MG, Chen ZS, Shchaveleva I, et al. Characterization of the drug resistance and transport properties of multidrug resistance protein 6 (MRP6, ABCC6). Cancer Res, 2002, 62:6172-6177.
160. Ilias A, Urban Z, Seidl TL, et al. Loss of ATP-de pendent transport activity in pseudoxanthoma elasticum-as sociated mutants of human ABCC6 (MRP6). J Biol Chem, 2002, 277: 16860-16867.
161. Hopper E, Belinsky MG, Zeng H, et al. Analysis of the structure and expression pattern of MRP7 (ABCC10), a new member of the MRP subfamily. Cancer Lett, 2001, 162:181-191.
162. Takayanagi S, Kataoka T, Ohara O, et al. Human ATP-binding cassette transporter ABCC10: expression profile and p53-dependent upregulation. J Exp Ther Oncol, 2004, 4:239-246.
163. Kao HH, Chang MS, Cheng JF, et al. Genomic structure, gene expression, and promoter analysis of human multidrug resistance -associated protein 7. J Biomed Sci, 2003, 10:98-110.
164. Wooden SL, Kalb SR, Cotter RJ, et al. Cutting edge: HLA-E binds a peptide derived from the ATP-binding cassette transporter multidrug resistance-associated protein 7 and inhibits NK cell -mediated lysis. J Immunol, 2005, 175:1383-1387.
165. Bessho Y, Oguri T, Ozasa H, et al. ABCC10/MRP7 is associated with vinorelbine resistance in non -small cell lung cancer. Oncol Rep, 2009, 21:263-268.
166. Huisman MT, Chhatta AA, van Tellingen O, et al. MRP2 (ABCC2) transports taxanes and confers paclitaxel resistance and both processes are stimulated by probenecid. Int J Cancer, 2005, 116:824-829.
167. Hopper-Borge E, Xu X, Shen T, et al. Human multidrug resistance protein 7 (ABCC10) is a resistance factor for nucleoside analogues and epothilone B. Cancer Res, 2009, 69: 178-184.
168. Hopper-Borge EA, Churchill T, Paulose C, et al. Contribution of ABCC10 (MRP7) to in vivo paclitaxel resistance as assessed in ABCC10(-/-) mice. Cancer Res, 2011, 71:3649-3657.
169. Risinger AL, Jackson EM, Polin LA, et al. The taccalonolides: microtubule stabilizers that circumvent clinically relevant taxane resistance mechanisms. Cancer Res, 2008, 68:8881-8888.
170. Chen ZS, Hopper-Borge E, Belinsky MG, et al. Characterization of the transport properties of human multidrug resistance protein 7 (MRP7, ABCC10). Mol Pharmacol, 2003, 63:351-358.
171. Naramoto H, Uematsu T, Uchihashi T, et al. Multidrug resistance-associated protein 7 expression is involved in cross-resistance to docetaxel in salivary gland adenocarcinoma cell lines. Int J Oncol, 2007, 30:393-401.
172. Oguri T, Ozasa H, Uemura T, et al. MRP7/ABCC10 expression is a predictive biomarker for the resistance to paclitaxel in non -small cell lung cancer. Mol Cancer Ther, 2008, 7:1150-1155.
173. Dabrowska M, Sirotnak FM. Regulation of transcription of the human MRP7 gene. Characteristics of the basal promoter and identification of tumor-de rived transcripts encoding additional 5' end heterogeneity. Gene, 2004, 341:129-139.
174. Bera TK, Lee S, Salvatore G, et al. MRP8, a new member of ABC transporter superfamily, identified byest database mining and gene prediction program, is highly expressed in breast cancer. Mol Med, 2001, 7:509-516.
175. Yabuuchi H, Shimizu H, Takayanagi S, et al. Multiple splicing variants of two new human ATP-binding cassette transporters, ABCC11 and ABCC12. Biochem Biophys Res Commun, 2001, 288:933-939.
176. Tammur J, Prades C, Arnould I, et al. Two new genes from the human ATP-binding cassette transporter superfamily, ABCC11 and ABCC12, tandemly duplicated on chromosome 16q12. Gene, 2001, 273:89-96.
177. Bortfeld M, Rius M, Konig J, et al. Human multidrug resistance protein 8 (MRP8/ABCC11), an apical efflux pump for steroid sulfates, is an axonal protein of the CNS and peripheral nervous system. Neuroscience, 2006, 137:1247-1257.
178. Reid G, Wielinga P, Zelcer N, et al. The human multidrug resistance protein MRP4 functions as a prostaglandin efflux transporter and is inhibited by nonsteroidal anti-inflammatory drugs. Proc Natl Acad Sci U S A, 2003, 100:9244-9249.
179. Chen ZS, Guo Y, Belinsky MG, et al. Transport of bile acids, sulfated steroids, estradiol 17-beta-D -glucuronide, and leukotriene C4 by human multidrug resistance protein 8 (ABCC11). Mol Pharmacol, 2005, 67:545-557.
180. Guo Y, Kotova E, Chen ZS, et al. MRP8, ATP-binding cassette c11 (ABCC11), is a cyclic nucleotide efflux pump and a resistance factor for fluoropyrimidines 2', 3'-di deoxycytidine and 9'-(2 '-ph osphonylmethoxyethyl)adenine. J Biol Chem, 2003, 278: 29509-29514.
181. Guo Y, Kock K, Ritter CA, et al. Expression of ABCC-type nucleotide exporters in blasts of adult acute myeloid leukemia: relation to long-term survival. Clin Cancer Res, 2009, 15:1762-1769.
182. Yabuuchi H, Takayanagi S, Yoshinaga K, et al. ABCC13, an unusual truncated ABC transporter, is highly expressed in fetal human liver. Biochem Biophys Res Commun, 2002, 299:410-417.
183. Annilo T, Dean M. Degeneration of an ATP-binding cassette transporter gene, ABCC13, in different mammalian lineages. Genomics, 2004, 84:34-46.
184. Tomita H, Nagamitsu S, Wakui K, et al. Paroxysmal kinesigenic choreoathetosis locus maps to chromosome 16p11.2 -q12.1. Am J Hum Genet, 1999, 65:1688-1697.
185. Bera TK, Iavarone C, Kumar V, et al. MRP9, an unusual truncated member of the ABC transporter superfamily, is highly expressed in breast cancer. Proc Natl Acad Sci U S A, 2002, 99:6997-7002.
186. Ono N, Van der Heijden I, Scheffer GL, et al. Multidrug resistance-associated protein 9 (ABCC12) is present in mouse and boar sperm. Biochem J, 2007, 406:31-40.
187. Zelcer N, Saeki T, Bot I, et al. Transport of bile acids in multidrug-re sistance-pr otein 3-overexpressing cells cotransfected with the ileal Na +- de pendent bile-ac id transporter. Biochem J, 2003, 369:23-30.
188. Gillet JP, Efferth T, Remacle J. Chemotherapy-in duced resistance by ATP-binding cassette transporter genes. Biochim Biophys Acta, 2007, 1775:237-262.